We aim to bridge the gap between HCPs and patients as treatment selection moves towards shared decision making. Common Ground is a platform that will aid HCPs in three ways: 1) A proprietary tool to facilitate treatment selection; 2) Providing quick access to critical treatment information; 3) Latest updates on medical advancements with customizable presets. The platform will provide filtered treatment options based on patients' priorities, compare drugs, and give the latest articles and updates.

2. We aim to bridge the gap between HCPs and Patients
as treatment selection processes move towards a
shared decision making model.
Common Ground™ is a platform that will aid HCPs in 3 ways:
Proprietary tool for
facilitating treatment
selection process
Providing a quick resource
for critical information
for treatments
Latest updates on
medical advancements
with customisable pre-sets
+
- Treatments Articles Platform

3. PATIENT
REPORT
TREATMENT
COMPARISON TOOL
APPROVED
TREATMENT
OPTIONS
TREATMENT
INFORMATION
ARTICLES

4. ICONS
TOUCH SCREEN FUNCTIONS
Phase III
Slide Left:
Decrease speed of audio
Slide Right:
Increase speed of audio
Touch and Hold:
Highlight sentence
Double blind
test
Hazard Ratio Positve Value

5. Audio aid
Hello
Doctor
Landing
Patient’s
Data Log
Search Navigation
+ Articles
+ Common Ground
Filtered treatment options
+ Patients piorities
+ Drug comparison
Login / Register
Articles
Drug
Info.
Common
Ground
+ more info
Medical Assistant :
Patient
Aid
Lastest Videos
Articles
Lastest updates
Description
Interaction
Warning
Dosage

6. LANDING

7. RESULTS
OVERVIEW

8. DATA
OVERVIEW

9. TREATMENT
INFO

10. Audio Feature
ABSTRACT
iPad 8:35 PM
NewTreatment1
ARTICLES Good Evening Dr. Banner
NewTreatment1 in Metastatic Prostate Cancer
before Chemotherapy
SUMMARY FULL ARTICLE NOTES
16.34
mins
BACKGROUND
Enzalutamide is an oral androgen-receptor inhibitor that prolongs
survival in men with metastatic castration-resistant prostate cancer in
whom the disease has pro- gressed after chemotherapy. New treatment
options are needed for patients with metastatic prostate cancer who
have not received chemotherapy, in whom the disease has progressed
despite androgen-deprivation therapy.
RESULTS
METHODS
NEW
The study was stopped after a planned interim analysis,
conducted when 540 deaths had been reported, showed a
benefit of the active treatment. The rate of radio-graphic
progression-free survival at 12 months was 65% among patients
treated with enzalutamide, as compared with 14% among
patients receiving placebo (81% risk reduction; hazard ratio in
the enzalutamide group, 0.19; 95% confidence inter- val [CI], 0.15
to 0.23; P<0.001). A total of 626 patients (72%) in the
enzalutamide group, as compared with 532 patients (63%) in the
placebo group, were alive at the data-cutoff date (29% reduction
in the risk of death; hazard ratio, 0.71; 95% CI, 0.60 to 0.84;
P<0.001). The benefit of enzalutamide was shown with respect to
all secondary end points, including the time until the initiation of
cytotoxic chemo- therapy (hazard ratio, 0.35), the time until the
In this double-blind, phase 3 study, we randomly assigned 1717
patients to receive either enzalutamide (at a dose of 16V0 mg) or
placebo once daily. The coprimary end points were radiographic
progression-free survival and overall survival.

11. NOTES
iPad 8:35 PM
NOTES
SUMMARY FULL ARTICLE NOTES
16.34
mins
NewTreatment1
RESULTS
METHODS
The coprimary end points were radiographic progression-free
survival and overall survival.
The rate of radio- graphic progression-free survival at 12 months
was 65% among patients treated with enzalutamide, as
compared with 14% among patients receiving placebo (81% risk
reduction; hazard ratio in the enzalutamide group, 0.19; 95%
confidence inter- val [CI], 0.15 to 0.23; P<0.001).

12. thank you
&
Ben
Melissa
Micky
Amanda